Tech Company Financing Transactions
CureVac Funding Round
On 11/14/2016, CureVac announced $29.5 million in funding from private investors.
Transaction Overview
Company Name
Announced On
11/14/2016
Transaction Type
Venture Equity
Amount
$29,500,000
Round
Undisclosed
Investors
Proceeds Purpose
CureVac plans to utilize these funds to advance the development of its innovative messenger RNA (mRNA) product portfolio.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
15 Paul-Ehrlich-Strasse
Tübingen, 72076
Germany
Tübingen, 72076
Germany
Phone
Website
Email Address
Overview
CureVac (Nasdaq: CVAC) is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Menichella
Chief Financial Officer
Pierre Kemula
Chief Operating Officer
Franz-Werner Haas
Chief Scientific Officer
Mariola Fotin-Mleczek
Founder
Ingmar Hoerr
VP - Product Management
Florian Mülbe
Browse more venture capital transactions:
Prev: 11/14/2016: Voltaiq venture capital transaction
Next: 11/14/2016: PERQ venture capital transaction
Share this article
About Database of VC Transactions
We report on tech company VC transactions. All VC database entries reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs